Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab Rollover Study in Advanced Solid Tumors
NCT04058756Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Apr 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 17
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in solid tumor (advanced stage), sponsored by Novartis. Primary endpoints: Frequency and nature of Adverse Events and Serious Adverse Events at 5 years and Number of subjects with PDR001 dose interruption and/or reduction at 5 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
spartalizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04058756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058756.